Thursday’s Midday Movers: Clovis Oncology (CLVS), ACADIA Pharmaceuticals (ACAD), Amarin (AMRN), Karyopharm Therapeutics (KPTI)

By Carrie Williams

So far Thursday, December 5, NASDAQ is down -1.32% and the S&P is down -0.91%. Here are this morning’s most active stocks: Clovis Oncology (CLVSResearch Report), ACADIA Pharmaceuticals (ACADResearch Report), Amarin (AMRNResearch Report) and Karyopharm Therapeutics (KPTIResearch Report).

Clovis Oncology is down -22.78% in midday trading to $9.22. Shares opened today at $11.94. The company has a 52-week low of $2.93 and a 52-week high of $32.05. On the Street’s front, the average 12-month analyst price target for the stock is $11.42, marking a -4.36% potential downside from current levels. In a report issued on November 19, Evercore ISI analyst Joshua Schimmer downgraded CLVS to Hold, with a price target of $8.00, which represents a potential downside of 33% from where the stock is currently trading. Separately, on November 8, H.C. Wainwright’s Edward White reiterated a Buy rating on the stock and has a price target of $36.00. In the last 30 days, insiders purchased $2,468 worth of CLVS shares.

ACADIA Pharmaceuticals is down -4.96% in midday trading to $50.35. Shares opened today at $52.98. The company has a 52-week low of $14.01 and a 52-week high of $53.70. On the Street’s front, the average 12-month analyst price target for the stock is $55.58, marking a 4.91% potential upside from current levels. In a report released today, Needham analyst Alan Carr maintained a Buy rating on ACAD, with a price target of $60.00, which implies an upside of 13% from current levels. Separately, on November 7, J.P. Morgan’s Cory Kasimov maintained a Hold rating on the stock and has a price target of $35.00. In the last 30 days, insiders purchased $100.2K worth of ACAD shares. Over the last 3 months, the insider sentiment on ACADIA Pharmaceuticals has been neutral based on 12 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Amarin is down -4.37% in midday trading to $21.84. Shares opened today at $22.84. The company has a 52-week low of $11.78 and a 52-week high of $24.67. On the Street’s front, the average 12-month analyst price target for the stock is $28.11, marking a 23.07% potential upside from current levels. In a report issued on December 3, Roth Capital analyst Yasmeen Rahimi reiterated a Buy rating on AMRN, with a price target of $31.00, which implies an upside of 36% from current levels. Separately, on November 19, Oppenheimer’s Leland Gershell initiated coverage with a Sell rating on the stock and has a price target of $7.00. Over the last 3 months, the insider sentiment on Amarin has been positive based on 64 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Karyopharm Therapeutics is down -4.17% in midday trading to $17.45. Shares opened today at $18.21. The company has a 52-week low of $3.92 and a 52-week high of $18.70. On the Street’s front, the average 12-month analyst price target for the stock is $23.60, marking a 29.60% potential upside from current levels. In a report issued on November 6, Wedbush analyst David Nierengarten maintained a Buy rating on KPTI, with a price target of $18.00, which represents a slight downside potential from current levels.

Trending Stocks Based on Insider Activity >>